Mass screening for colorectal cancer in a population of two million older adults in Guangzhou, China
2019 · Scientific Reports · 60 citations
https://doi.org/10.1038/s41598-019-46670-2
Z
Zhiqiang Feng
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
143
Papers
1.7K
Citations
25
h-index
56
i10-index
Zhiqiang Feng is an academic researcher from Shanghai Institute of Geological Survey. The author has contributed to research in topics: Colorectal Cancer Screening and Detection & Gastric Cancer Management and Outcomes & Cancer Immunotherapy and Biomarkers. The author has an h-index of 25, co-authored 122 publications.
ORCID: 0009-0002-5093-6010Papers by this author
worksYPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
2022 · Acta Pharmaceutica Sinica B · 26 citations
https://doi.org/10.1016/j.apsb.2022.02.031
The prebiotics 2′-fucosyllactose prevent high-fat diet induced obesity via the promotion of thermogenesis and modulation of gut microbiota
2024 · Journal of Functional Foods · 7 citations
https://doi.org/10.1016/j.jff.2024.106287
Preparation of an aqueous colloidal dispersion of myofibrillar proteins: A synergistic strategy integrating nonenzymatic glycation and exogenous amino acids
2025 · Food Chemistry · 4 citations
https://doi.org/10.1016/j.foodchem.2025.143609
Fault Analysis of Transmission Line Based on Induced Traveling Waves Between Wires
2024 · 1 citations
https://doi.org/10.1109/ifeea64237.2024.10878516
Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
2023 · Acta Pharmaceutica Sinica B · 0 citations
https://doi.org/10.1016/j.apsb.2023.05.003
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat